Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The capsid proteins of the poliovirus type 1 Mahoney strain are structural proteins forming the outer shell of the virus. They protect the viral RNA genome, mediate host cell entry via PVR/CD155 receptor binding, and determine antigenicity. The capsid comprises 60 copies each of VP1, VP2, VP3 (surface-exposed), and VP4 (internal), all derived from the N-terminal region of a polyprotein. The Mahoney strain is a reference wild-type strain crucial for research and vaccine development (both inactivated and live attenuated). Determinants within surface loops, especially the VP1 B-C loop, are key to neurovirulence studies. No coreceptor is required for entry.
Viral entry inhibition (theoretical, through blocking receptor binding or capsid uncoating)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Type I Mahoney Strain Capsid Proteins (PV1 Capsid Proteins).